Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program: Correlation With Outcomes

Study Questions:

Does administration of serelaxin, a recombinant form of human relaxin-2 (a hormone that assists in adaptation to pregnancy-mediated physiologic cardiovascular changes), to patients with acute heart failure (HF) reduce myocardial and end-organ damage?